TouchONCOLOGY got the chance to catch up with Rocio Garcia-Carbonero (Hospital Universitario 12 de Octubre, Madrid, Spain) on the use of octreotide acetate with axitinib for the treatment of patients with non-pancreatic neuroendocrine tumors (Clinical Trial Identifier: NCT01744249). The abstract ‘A phase II/III randomized double-blind study of octreotide acetate with axitinib versus octreotide acetate with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107).’ (ABSTRACT NUMBER: 360) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
Questions
- What is the rationale for the combination of octreotide with axitinib in the treatment of patients with non-pancreatic neuroendocrine tumors (NETs)? (0:20)
- Could you tell us a little about the AXINET trial-GETNE-1107 and its findings? (2:09)
- Since the combination of axitinib and octreotide failed to demonstrate a significant improvement in PFS compared with placebo and octreotide, what will be the next steps in the investigation of axitinib for non-pancreatic NETs? (6:04)
Disclosures: RGC has provided scientific advice and/or received honoraria or funding for continuous medical education from AAA, Advanz Pharma, Bayer, HMP, Ipsen, Merck, Midatech Pharma, MSD, Novartis, PharmaMar, Pfizer, Pierre Fabre, Roche, Servier and Sanofi, and has received research support from Pfizer, BMS and MSD.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
